Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Glioblastoma | Research

TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO

Authors: Yike Chen, Xiaohui Xu, Kaikai Ding, Tianchi Tang, Feng Cai, Haocheng Zhang, Zihang Chen, Yangjian Qi, Zaixiang Fu, Ganggui Zhu, Zhangqi Dou, Jinfang Xu, Gao Chen, Qun Wu, Jianxiong Ji, Jianmin Zhang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Background

Ubiquitination plays an important role in proliferating and invasive characteristic of glioblastoma (GBM), similar to many other cancers. Tripartite motif 25 (TRIM25) is a member of the TRIM family of proteins, which are involved in tumorigenesis through substrate ubiquitination.

Methods

Difference in TRIM25 expression levels between nonneoplastic brain tissue samples and primary glioma samples was demonstrated using publicly available glioblastoma database, immunohistochemistry, and western blotting. TRIM25 knockdown GBM cell lines (LN229 and U251) and patient derived GBM stem-like cells (GSCs) GBM#021 were used to investigate the function of TRIM25 in vivo and in vitro. Co-immunoprecipitation (Co-IP) and mass spectrometry analysis were performed to identify NONO as a protein that interacts with TRIM25. The molecular mechanisms underlying the promotion of GBM development by TRIM25 through NONO were investigated by RNA-seq and validated by qRT-PCR and western blotting.

Results

We observed upregulation of TRIM25 in GBM, correlating with enhanced glioblastoma cell growth and invasion, both in vitro and in vivo. Subsequently, we screened a panel of proteins interacting with TRIM25; mass spectrometry and co-immunoprecipitation revealed that NONO was a potential substrate of TRIM25. TRIM25 knockdown reduced the K63-linked ubiquitination of NONO, thereby suppressing the splicing function of NONO. Dysfunctional NONO resulted in the retention of the second intron in the pre-mRNA of PRMT1, inhibiting the activation of the PRMT1/c-MYC pathway.

Conclusions

Our study demonstrates that TRIM25 promotes glioblastoma cell growth and invasion by regulating the PRMT1/c-MYC pathway through mediation of the splicing factor NONO. Targeting the E3 ligase activity of TRIM25 or the complex interactions between TRIM25 and NONO may prove beneficial in the treatment of GBM.
Appendix
Available only for authorised users
Literature
1.
Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–46.PubMedCrossRef
2.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.PubMedCrossRef
3.
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in Neuro-Oncology The Avenue to a cure for malignant glioma. Ca-a Cancer Journal for Clinicians. 2010;60(3):166–93.PubMedPubMedCentralCrossRef
4.
Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, et al. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2017;35(3):361–69.PubMedCrossRef
5.
Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Experimental Clin Cancer Res. 2022;41(1):142.CrossRef
6.
Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005;23(10):2411–22.PubMedCrossRef
7.
Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neurooncology. 2014;16(12):1575–84.
8.
Liu CA, Chang CY, Hsueh KW, Su HL, Chiou TW, Lin SZ, et al. Migration/Invasion of Malignant gliomas and implications for Therapeutic Treatment. Int J Mol Sci. 2018;19(4):1115.PubMedPubMedCentralCrossRef
9.
Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39(4):509–28e20.PubMedPubMedCentralCrossRef
10.
Noorani I, Mischel PS, Swanton C. Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. Nat Reviews Clin Oncol. 2022;19(11):733–43.CrossRef
11.
Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE, Vucic D. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 2021;28(2):591–605.PubMedPubMedCentralCrossRef
12.
Cervia LD, Shibue T, Borah AA, Gaeta B, He L, Leung L, et al. A Ubiquitination Cascade regulating the Integrated Stress Response and survival in Carcinomas. Cancer Discov. 2023;13(3):766–95.PubMedCrossRef
13.
Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23(12):842–62.PubMedCrossRef
14.
Zheng N, Shabek N. Ubiquitin ligases: structure, function, and Regulation. Annu Rev Biochem. 2017;86:129–57.PubMedCrossRef
15.
Lauwers E, Jacob C, Andre B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J Cell Biol. 2009;185(3):493–502.PubMedPubMedCentralCrossRef
16.
Akutsu M, Dikic I, Bremm A. Ubiquitin chain diversity at a glance. J Cell Sci. 2016;129(5):875–80.PubMed
17.
Humphreys LM, Smith P, Chen ZY, Fouad S, D’Angiolella V. The role of E3 ubiquitin ligases in the development and progression of glioblastoma. Cell Death Differ. 2021;28(2):522–37.PubMedPubMedCentralCrossRef
18.
Wang D, Ma LN, Wang B, Liu J, Wei WY. E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev. 2017;36(4):683–702.PubMedCrossRef
19.
Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Therapy. 2020;5(1):11.CrossRef
20.
Koliopoulos MG, Esposito D, Christodoulou E, Taylor IA, Rittinger K. Functional role of TRIM E3 ligase oligomerization and regulation of catalytic activity. EMBO J. 2016;35(11):1204–18.PubMedPubMedCentralCrossRef
21.
Lin H, Jiang M, Liu L, Yang Z, Ma Z, Liu S, et al. The long noncoding RNA Lnczc3h7a promotes a TRIM25-mediated RIG-I antiviral innate immune response. Nat Immunol. 2019;20(7):812–23.PubMedCrossRef
22.
Gack MU, Kirchhofer A, Shin YC, Inn KS, Liang C, Cui S, et al. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci USA. 2008;105(43):16743–8.ADSPubMedPubMedCentralCrossRef
23.
Chen ST, Chen L, Lin DS, Chen SY, Tsao YP, Guo H, et al. NLRP12 regulates anti-viral RIG-I activation via Interaction with TRIM25. Cell Host Microbe. 2019;25(4):602–16e7.PubMedPubMedCentralCrossRef
24.
Liu Y, Tao S, Liao L, Li Y, Li H, Li Z, et al. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. Nat Commun. 2020;11(1):348.ADSPubMedPubMedCentralCrossRef
25.
Li F, Sun Q, Liu K, Zhang L, Lin N, You K, et al. OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity. Nat Commun. 2020;11(1):4184.ADSPubMedPubMedCentralCrossRef
26.
Zhou S, Peng J, Xiao L, Zhou C, Fang Y, Ou Q, et al. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. Cell Death Dis. 2021;12(5):463.PubMedPubMedCentralCrossRef
27.
Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, et al. The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development. Cell Death Differ. 2020;27(2):420–33.PubMedCrossRef
28.
Takayama KI, Suzuki T, Tanaka T, Fujimura T, Takahashi S, Urano T, et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. Oncogene. 2018;37(16):2165–80.PubMedCrossRef
29.
Ji J, Ding K, Luo T, Zhang X, Chen A, Zhang D, et al. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Cell Death Differ. 2021;28(1):367–81.PubMedCrossRef
30.
31.
Xie R, Chen X, Cheng L, Huang M, Zhou Q, Zhang J, et al. NONO inhibits lymphatic metastasis of bladder Cancer via Alternative Splicing of SETMAR. Mol Ther. 2021;29(1):291–307.PubMedCrossRef
32.
Kathman SG, Koo SJ, Lindsey GL, Her HL, Blue SM, Li H, et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nat Chem Biol. 2023;19(7):825–36.PubMedPubMedCentralCrossRef
33.
Wang X, Han M, Wang S, Sun Y, Zhao W, Xue Z, et al. Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention. Theranostics. 2022;12(12):5451–69.PubMedPubMedCentralCrossRef
34.
35.
Yan K, Ponnusamy M, Xin Y, Wang Q, Li P, Wang K. The role of K63-linked polyubiquitination in cardiac hypertrophy. J Cell Mol Med. 2018;22(10):4558–67.PubMedPubMedCentralCrossRef
36.
Das T, Park JK, Park J, Kim E, Rape M, Kim EE, et al. USP15 regulates dynamic protein-protein interactions of the spliceosome through deubiquitination of PRP31. Nucleic Acids Res. 2017;45(8):4866–80.PubMedPubMedCentral
37.
Song EJ, Werner SL, Neubauer J, Stegmeier F, Aspden J, Rio D, et al. The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev. 2010;24(13):1434–47.PubMedPubMedCentralCrossRef
38.
Bellare P, Small EC, Huang X, Wohlschlegel JA, Staley JP, Sontheimer EJ. A role for ubiquitin in the spliceosome assembly pathway. Nat Struct Mol Biol. 2008;15(5):444–51.PubMedPubMedCentralCrossRef
39.
Li Z, Wang D, Lu J, Huang B, Wang Y, Dong M, et al. Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 2020;27(12):3226–42.PubMedPubMedCentralCrossRef
40.
41.
Yao B, Gui T, Zeng X, Deng Y, Wang Z, Wang Y, et al. PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Med. 2021;13(1):58.PubMedPubMedCentralCrossRef
42.
Hsu WJ, Chen CH, Chang YC, Cheng CH, Tsa IY, Lin CW. PRMT1 confers resistance to Olaparib via modulating MYC signaling in Triple-negative breast Cancer. J Personalized Med. 2021;11(10):1009.CrossRef
43.
Wang W, Ma Y, Huang M, Liang W, Zhao X, Li Q, et al. Asymmetrical arginine dimethylation of histone H4 by 8-oxog/OGG1/PRMT1 is essential for oxidative stress-induced transcription activation. Free Radic Biol Med. 2021;164:175–86.PubMedCrossRef
44.
45.
Heikel G, Choudhury NR, Michlewski G. The role of Trim25 in development, disease and RNA metabolism. Biochem Soc Trans. 2016;44(4):1045–50.PubMedCrossRef
46.
Mei P, Xie F, Pan J, Wang S, Gao W, Ge R, et al. E3 ligase TRIM25 ubiquitinates RIP3 to inhibit TNF induced cell necrosis. Cell Death Differ. 2021;28(10):2888–99.PubMedPubMedCentralCrossRef
47.
Han S, Wang R, Zhang Y, Li X, Gan Y, Gao F, et al. The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022;18(6):2292–303.PubMedPubMedCentralCrossRef
48.
Zhang X, Meng T, Cui S, Liu D, Pang Q, Wang P. Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (review). Int J Oncol. 2022;61(1):84.PubMedPubMedCentralCrossRef
49.
50.
51.
52.
Wang L, Zhu B, Wang S, Wu Y, Zhan W, Xie S, et al. Regulation of glioma migration and invasion via modification of Rap2a activity by the ubiquitin ligase Nedd4-1. Oncol Rep. 2017;37(5):2565–74.PubMedPubMedCentralCrossRef
53.
Zhang J, Yang Z, Ou J, Xia X, Zhi F, Cui J. The F-box protein FBXL18 promotes glioma progression by promoting K63-linked ubiquitination of Akt. FEBS Lett. 2017;591(1):145–54.PubMedCrossRef
54.
Wald JH, Hatakeyama J, Printsev I, Cuevas A, Fry WHD, Saldana MJ, et al. Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 2017;36(36):5158–67.PubMedPubMedCentralCrossRef
55.
Dong B, Horowitz DS, Kobayashi R, Krainer AR. Purification and cDNA cloning of HeLa cell p54nrb, a nuclear protein with two RNA recognition motifs and extensive homology to human splicing factor PSF and Drosophila NONA/BJ6. Nucleic Acids Res. 1993;21(17):4085–92.PubMedPubMedCentralCrossRef
56.
Hu Z, Dong L, Li S, Li Z, Qiao Y, Li Y, et al. Splicing Regulator p54(nrb) /Non-POU domain-containing octamer-binding protein enhances carcinogenesis through Oncogenic Isoform switch of MYC Box-Dependent interacting protein 1 in Hepatocellular Carcinoma. Hepatology (Baltimore MD). 2020;72(2):548–68.PubMedCrossRef
57.
58.
59.
60.
Wong JJ, Ritchie W, Ebner OA, Selbach M, Wong JW, Huang Y, et al. Orchestrated intron retention regulates normal granulocyte differentiation. Cell. 2013;154(3):583–95.PubMedCrossRef
61.
Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Mönch K, Thoren LA, Nielsen FC, et al. NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev. 2008;22(10):1381–96.PubMedPubMedCentralCrossRef
62.
Brady LK, Wang H, Radens CM, Bi Y, Radovich M, Maity A, et al. Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. PLoS Biol. 2017;15(9):e2002623.PubMedPubMedCentralCrossRef
63.
Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, et al. Intron retention: a common splicing event within the human kallikrein gene family. Clin Chem. 2005;51(3):506–15.PubMedCrossRef
64.
Dumbović G, Braunschweig U, Langner HK, Smallegan M, Biayna J, Hass EP, et al. Nuclear compartmentalization of TERT mRNA and TUG1 lncRNA is driven by intron retention. Nat Commun. 2021;12(1):3308.ADSPubMedPubMedCentralCrossRef
Metadata
Title
TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO
Authors
Yike Chen
Xiaohui Xu
Kaikai Ding
Tianchi Tang
Feng Cai
Haocheng Zhang
Zihang Chen
Yangjian Qi
Zaixiang Fu
Ganggui Zhu
Zhangqi Dou
Jinfang Xu
Gao Chen
Qun Wu
Jianxiong Ji
Jianmin Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-02964-6

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway

Research

Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

Research

IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma

Research

Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics

Research

PELI1: key players in the oncogenic characteristics of pancreatic Cancer

Research

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits